Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2007 Apr 11;45(6):2000–2001. doi: 10.1128/JCM.00287-07

Clinical Evaluation of the Sensititre YeastOne Plate for Testing Susceptibility of Filamentous Fungi to Posaconazole

Reena Patel 1, Cara Mendrick 1, Cindy C Knapp 2, Roger Grist 2, Paul M McNicholas 1,*
PMCID: PMC1933054  PMID: 17428931

Abstract

Sensititre YeastOne colorimetric antifungal panels were compared with the CLSI (formerly NCCLS) M38-A reference method for testing the susceptibility of filamentous fungi to posaconazole; agreement (±2 log2 dilutions) between the two methods was 97%. These data confirm the utility of YeastOne panels for measuring the susceptibility of filamentous fungi to posaconazole.


The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) M38-A reference method is approved for testing the susceptibility of filamentous molds that cause invasive fungal infections, including Aspergillus spp., Fusarium spp., Rhizopus arrhizus, Pseudallescheria boydii (anamorph, Scedosporium apiospermum), Sporothrix schenckii, and other opportunistic pathogenic molds, to antifungal agents (1). However, the method is labor-intensive and requires 48 h of incubation (R. arrhizus requires 24 h) before MIC results can be read. In contrast, the Sensititre YeastOne colorimetric antifungal panel (TREK Diagnostic Systems, Cleveland, OH) is a commercially prepared plate that requires only the addition of a medium containing the fungal inoculum, and MICs can be read after 24 h. Furthermore, reading of the end point is facilitated by the inclusion of a metabolic dye, alamarBlue.

Posaconazole is a new azole antifungal with a broad spectrum of activity, including activity against filamentous molds, such as the zygomycetes, that were not previously regarded as being susceptible to azoles (4). The goal of this study was to compare the reproducibility of the Sensititre YeastOne method with that of the CLSI reference method for testing the susceptibility of a broad spectrum of filamentous fungi to posaconazole.

In vitro susceptibility testing methods.

Two hundred forty-nine filamentous fungi from the Schering-Plough Research Institute fungal collection were tested: 96 were Aspergillus fumigatus, 32 Aspergillus flavus, 20 Aspergillus niger, 19 Aspergillus terreus, 3 Aspergillus nidulans, 3 Aspergillus ustus, 3 Aspergillus versicolor, 3 Aspergillus oryzae, 14 Fusarium solani, 7 Fusarium oxysporum, 6 Fusarium moniliforme, 6 Fusarium proliferatum, 8 Fusarium spp., 3 Mucor spp., 3 Absidia spp., 17 Rhizopus spp., 4 Rhizopus arrhizus, and 2 Rhizopus microsporus.

Reference MICs were determined using the broth microdilution technique as described in the CLSI M38-A document (1). Posaconazole concentrations ranged from 0.08 to 8 μg/ml; the last well was a positive control. Plates were incubated for either 24 h (Rhizopus spp. only) or 48 h at 35°C. The end point was the first well showing complete growth inhibition.

In the Sensititre YeastOne colorimetric antifungal susceptibility panel, the posaconazole concentrations ranged from 0.08 to 8 μg/ml; the last well was a positive control. The panels were inoculated according to the manufacturer's instructions. The colorimetric MIC for each isolate was determined after a 24-h incubation at 35°C and was the lowest antifungal concentration showing inhibition of growth. Fungal growth in the wells was evident as a change in the colorimetric growth indicator, alamarBlue, from blue (negative) to pink (positive); therefore, the MIC was interpreted as the well with the lowest drug concentration in which the growth indicator remained blue. The following CLSI-approved quality control (QC) strains were run on each test occasion: Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, and Paecilomyces variotii ATCC MYA-3630.

In vitro susceptibility testing results.

The methods were considered to be in agreement if the MICs determined using Sensititre YeastOne were within 2 doubling dilutions of those obtained using the CLSI reference method. Isolates for which the values were outside this range were retested. The MICs for all the QC isolates, including the recently approved mold QC isolate P. variotii ATCC MYA-3630, were all within range. The overall agreement (range, ±2 log2 dilutions) between the Sensititre YeastOne MICs and the corresponding CLSI reference method was 97% (Table 1). There were seven isolates (four A. fumigatus, two R. arrhizus, and one A. ustus isolate) for which the MICs did not agree within the prescribed dilution range; for all seven isolates, the Sensititre YeastOne MICs were higher than the reference values, which ranged from 0.03 to 2 μg/ml. Both tests were repeated, and all seven isolates gave concordant results; for six of the seven, the results were identical for the two methods, while for the remaining isolate, agreement was within 1 doubling dilution.

TABLE 1.

Agreement between CLSI reference method M38-A and the Sensititre YeastOne method for testing the susceptibility of filamentous molds

Test organism(s) No. of strains MICa by CLSI/MIC by YO
% Agreement within the following log2 dilution
MIC90 Range ±2 ±1 0
All isolates 249 97 94 56
Aspergillus 179 97 94 50
    A. fumigatus 96 1/1 0.015->8/0.015->8 96 94 54
    A. flavus 32 0.5/0.25 0.12-1/0.06-0.25 100 91 34
    A. niger 20 0.25/0.25 0.03-0.25/0.03-0.25 100 100 70
    A. terreus 19 0.25/0.25 0.015-0.5/0.03-0.5 100 95 32
    A. nidulans 3 b 0.015-0.06/0.015-0.06 100 100 33
    A. oryzae 3 0.12-0.5/0.12-0.25 100 100 33
    A. ustus 3 2->8/>8 67 67 67
    A. versicolor 3 0.06->8/0.03->8 100 100 67
Fusarium 41 100 98 90
    F. solani 14 >8/>8 >8/>8 100 100 100
    Fusarium spp. 8 0.5->8/0.5->8 100 100 88
    F. oxysporum 7 2->8/2->8 100 100 100
    F. moniliforme 6 1-2/1-2 100 100 67
    F. proliferatum 6 4->8/1->8 100 83 83
Zygomycetes 29 93 86 45
    Absidia
        Absidia spp. 2 1-2/0.5 100 50 0
        A. corymbifera 1 2/1 100 100 0
    Mucor
        M. circinelloides 1 2/0.5 100 0 0
        M. ramosissimus 1 2/1 100 100 0
        Mucor spp. 1 2/2 100 100 100
    Rhizopusc 96 96 57
        Rhizopus spp. 17 1/1 0.06->8/0.12->8 100 100 47
        R. arrhizus 4 0.03-2/0.25->8 50 50 50
        R. microsporus 2 0.5/0.5 100 100 100
a

In micrograms per milliliter. YO, Sensititre YeastOne.

b

—, not determined. MIC90s were calculated only when >10 isolates were tested.

c

CLSI MICs were read after 24 h.

Laboratory-generated A. fumigatus mutants (2, 3) with reduced susceptibility to posaconazole were included in this study; for 2 isolates, MICs were >8 μg/ml, and for 11, MICs were ≥1 μg/ml. When these isolates were excluded from the analysis, the MIC at which 90% of isolates were inhibited (MIC90) was 0.5 μg/ml for A. fumigatus, in agreement with the findings of a previous survey (4). The Sensititre YeastOne method identified the two resistant A. fumigatus isolates, with MICs of >8 μg/ml. For 10 of the remaining 11 isolates, the Sensititre YeastOne MICs were within the prescribed agreement range. For the final isolate (CLSI MIC, 2 μg/ml), the Sensititre YeastOne MIC was >8 μg/ml; upon retesting, both methods returned values of 1 μg/ml. Similarly, the Fusarium isolates exhibiting reduced susceptibility to posaconazole were accurately identified using the Sensititre YeastOne method.

The high levels of agreement between the MICs obtained using Sensititre YeastOne and the CLSI reference method suggest the potential value of Sensititre YeastOne for use in the clinical laboratory to determine posaconazole MICs for filamentous mold isolates.

Footnotes

Published ahead of print on 11 April 2007.

REFERENCES

  • 1.Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. Clinical and Laboratory Standards Institute, Wayne, PA.
  • 2.Mann, P. A., R. Parmegiani, S.-Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, R. S. Hare, S. S. Walker, B. J. DiDomenico, and P. M. McNicholas. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob. Agents Chemother. 47:577-581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Nascimento, A. M., G. H. Goldman, S. Park, S. A. Marras, G. Delmas, U. Oza, K. Lolans, M. N. Dudley, P. A. Mann, and D. S. Perlin. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES